Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

MLA

Harbeck, Nadia, et al. Impact of PIK3CA Mutation Status on Immune Marker Response and PCR in the WSG-ADAPT HER2+/HR+ Phase II Trial. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1201319326&authtype=sso&custid=ns315887.

APA

Harbeck, N., Nitz, U., Christgen, M., Kates, R. E., Braun, M. W., Kummel, S., Schumacher, C., Potenberg, J., Malter, W., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Kleine-Tebbe, A., Liedtke, C., de Haas, S., Deurloo, R., Wuerstlein, R., Kreipe, H. H., & Gluz, O. (2018). Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

Chicago

Harbeck, Nadia, Ulrike Nitz, Matthias Christgen, Ronald E. Kates, Michael Wilhelm Braun, Sherko Kummel, Claudia Schumacher, et al. 2018. “Impact of PIK3CA Mutation Status on Immune Marker Response and PCR in the WSG-ADAPT HER2+/HR+ Phase II Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1201319326&authtype=sso&custid=ns315887.